Navigation Links
Study Adds to Evidence That Rituximab Slows Lymphoma Symptoms
Date:12/21/2010

TUESDAY, Dec. 21 (HealthDay News) -- New research provides more evidence that treating certain lymphoma patients with an expensive drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly increase life span, raising questions about whether it's worth taking.

People with lymphoma who are considering maintenance treatment "really need a discussion with [their] oncologist," said Dr. Steven T. Rosen, director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago.

The study involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a term that refers to cancers of the immune system. Though it can be fatal, most people live for at least 10 years after diagnosis.

There has been debate over whether people with the disease should take Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F. Hoffmann-La Roche, a pharmaceutical company that sells Rituxan, roughly half of the 1,019 participants took Rituxan, and the others did not. All previously had taken the drug right after receiving chemotherapy.

In the next three years, the study found, people taking the drug took longer, on average, to develop symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't take the drug. But the death rate over three years remained about the same, according to the report, published online Dec. 21 in The Lancet.

The drug "should now be considered as first-line treatment for these patients," wrote Dr. Gilles Salles of Hospices Civils de Lyon & Universite Claude Bernard in Lyon, France, and his research colleagues.

But Rosen said there's still a divide over use of the drug as maintenance therapy. "Physicians are falling into two groups," he said. "One says, 'There was no survival advantage, I'd just wait until you have progression and then re-treat you. That's not unreasonable.'"

Another group "would say that there's potentially better quality of life during the period without disease," Rosen said. "But the psychological benefits from not having any evidence of disease are hard to measure."

In a comment accompanying the report in The Lancet, Dr. Jonathan Friedberg, of the hematology and oncology division at the University of Rochester in Rochester, N.Y., wrote that "an analysis of cost-effectiveness would be very helpful."

"In an era of increased health-care costs, what benefit is necessary to justify the cost of this maintenance strategy, which at my institution would cost Medicare more than $60,000 per patient?" Friedberg asked.

He also described as premature the researchers' statement that maintenance therapy with the drug should be prescribed for all people with follicular lymphoma who are initially treated with rituximab plus chemotherapy.

"However, maintenance is an option," Friedberg said, adding that "the investigators are to be congratulated for this important contribution and are strongly encouraged to continue follow-up of these patients to answer the questions that remain."

More information

The U.S. National Cancer Institute has more on lymphoma.

-- Randy Dotinga

SOURCES: Steven T. Rosen, M.D., director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago; The Lancet, news release, Dec. 21, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. TV drama can be more persuasive than news program, study finds
4. Study carried out into biological risks of eating reptiles
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Study finds racial gaps continue in heart disease awareness
7. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Soothing infants with food focus of childhood obesity study
10. People with anxiety disorder less able to regulate response to negative emotions, study shows
11. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Adds to Evidence That Rituximab Slows Lymphoma Symptoms
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... is poised to once again host, Swirl, A Wine Tasting Event at the ...
(Date:2/5/2016)... ... February 05, 2016 , ... In ... across the country gathered at the La Valencia Hotel in San Diego, California ... Chicago was named the year’s most outstanding franchise, walking away with the coveted ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... gym use and find themselves having to wait longer to access the treadmills. It’s ... their New Year’s resolutions to lose weight and get in shape by joining gyms, ...
(Date:2/5/2016)... ... 2016 , ... Boar’s Head Brand®, one of the nation’s leading providers of ... Take the stress out of your party preparation – follow these easy, yet delicious ... of the game. , “The key to hosting a successful game-day party is creating ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... 2016 In response to the opioid abuse epidemic, ... for Medical Products and Tobacco, along with other FDA leaders, ... approach to opioid medications. The plan will focus on policies ... pain access to effective relief. --> ... Re-examine the risk-benefit paradigm for opioids and ensure that the ...
Breaking Medicine Technology: